Pluristem Therapeutics to Present at the 8th Israel Life Science Industry (ILSI) BioMed Conference
Business Wire
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Mr. Zami Aberman, President and CEO, has been invited to present at the ILSI-BioMed Conference on the topic "The Placenta - A Matchless Source for Cell Therapy." The presentation will take place on Tuesday, June 16, 2009 in the BioPharma Session at 5:20-5:40 pm local time, at the David InterContinental Hotel, Tel Aviv, Israel. In addition, Moran Meiron, Ph.D., Pluristem’s Research Director, was invited to present a poster titled “Paracrine and Immunological Characteristics of Placenta Derived MSC like Cells- Possible Mechanism of Action,” which will be on display from June 15 through 17, 2009 at the Posters Hall, in the Dan Panorama Hotel, Tel-Aviv, Israel.
“There is a keen interest in the field of cellular therapy, particularly in the niche of cell therapy where matching between the donor and the patient is not required,” stated Mr. Aberman. “The placenta is a great source for cell therapy, since it appears to be immune competent and not stimulate the immune response.” |
